Abstract: Fingolimod is a promising prodrug in attenuating multiple sclerosis and prolonging survival of organ allograft, with many other protective effects. Its mechanism of action is related to the internalization of sphingosine 1-phosphate receptors (S1PRs). Our previous study indicated that fingolimod eyedrops was efficacious in inhibiting ocular inflammation in a dry eye disease (DED) model of non-obese diabetic (NOD) mice. In the current study, we evaluated potential adverse effects of fingolimod eyedrops. Inbred 10-week-old BALB/c mice were randomly divided into four groups, fingolimod-treated groups at three different concentrations (0.01%, 0.1% and 0.5%) and a negative control group without intervention. Our results showed that in the 0.5% fingolimod group, adverse effects such as photophobia, catacleisis and corneal oedema were observed after 1 week of treatment. 1 month later, corneal opacity, oedema and neovascularization persisted till the mice were killed 2 months later. In contrast, there was no significant abnormality in the negative control group, and 0.01% and 0.1% fingolimod-treated groups. During a 2-month treatment period, we did not detect fingolimod, nor significant change in blood cells in peripheral blood, nor pathological changes in retina and systemic organs. Combined with our previous study and the current results, we recommend that an optimal range of safe and effective concentration of fingolimod as eyedrops is between 0.005% and 0.1%.
Dry eye disease (DED) is a disorder of the tear film due to tear deficiency or excessive evaporation, which causes damage to the interpalpebral ocular surface and is associated with symptoms of ocular discomfort. It involves multiple interacting mechanisms including a great range of signs and symptoms, while the core mechanism is considered to be tear hyperosmolarity and tear film instability [1] . The multi-factorial and extremely complicated pathogenesis and mechanisms of DED make its treatment quite difficult. Although a variety of treatments have been used, such as tear film substitute, autologous serum eyedrops combined with punctual plugs, anti-inflammation, etc., there is no specific cure for this disease [2] [3] [4] [5] . In the past two decades, cyclosporine A was found to significantly decrease conjunctival rose bengal staining, superficial punctate keratitis and ocular irritation symptoms in certain dry eye patients [6] . Treated eyes had a significant increase in conjunctival goblet cell density [7] . However, clinical trials also reported complaints about burning sensations after instillation although no significant systemic or ocular adverse events were detected [8] .
Fingolimod was first developed by Fujita et al. in collaboration with Yoshitomi Pharmaceuticals Ltd [9] . It was reported to produce lymphopenia by suppressing the recirculation of lymphocyte and sequestering them into lymph nodes and Peyer's patches without affecting their normal induction, proliferation and differentiation in secondary lymphoid organs [10] [11] [12] . In 2010, fingolimod was approved by the US. Food and Drug Administration as a first-line treatment for relapsing forms of multiple sclerosis. The most common serious adverse effects reported in previous studies were cardiovascular events, including bradycardia and firstdegree or second-degree atrioventricular block [13, 14] . Macular oedema was also reported in clinical studies, which was diagnosed within 3-4 months of treatment initiation in most cases [15] .
In our previous study, we showed that fingolimod eyedrops inhibited the inflammatory responses in a DED model in nonobese diabetic (NOD) mice. Tear film break-up test and phenol red cotton test were significantly improved in the drugtreated animals. Inflammatory mediators were greatly downregulated in the tear fluid, lacrimal gland and conjunctiva. Leucocytes in conjunctiva were greatly decreased. More importantly, the density and morphology of goblet cells and conjunctival epithelial cells were significantly normalized. These results indicated that fingolimod not only has a significant therapeutic effect in DED but also promotes the reestablishment of ocular surface tissue function. In that study, fingolimod was reconstituted into normal saline and prepared as eyedrops at three different concentrations (0.05%, 0.005% and 0.001%). We found the optimal therapeutic concentration range between 0.005% and 0.05% [16] .
It should be noted that our study was the first to describe the therapeutic effects of fingolimod eyedrops to treat DED in a rodent model. The results are interesting and encouraging. However, when we tried a higher concentration, we observed adverse reactions. In view of this, it is a necessity to assess the adverse effect profile of fingolimod eyedrops in order to define a safe therapeutic range for its future application. It is reported that most notably adverse effect of eyedrops is on the ocular surface. Conjunctival hyperaemia, decreased tear production and function and superficial punctate keratitis are among the most common signs seen on routine clinical examination. This can result in ocular discomfort due to dry eye and inflammatory irritation. The detailed mechanism of inflammatory response and/or direct toxicity of eyedrops have yet to be determined. They may also vary depending on drug concentrations [17] . In our study, we found that 0.5% fingolimod caused adverse reactions in ocular surface tissues of BALB/c mice. In contrast, there was no significant adverse effect in the 0.01% and 0.1% fingolimod-treated groups. In addition, we did not detect fingolimod in peripheral blood. We did not observe any abnormal sign in retina, selected organs and blood cells in peripheral blood.
Materials and Methods
Animal and reagent. Seventy-two (72) inbred 10-week-old BALB/c mice (Shanghai SLAC Laboratory Animal Co., Ltd., Chinese Academy of Sciences, Shanghai, China) were kept in pathogen-free conditions under constant ambient temperature (20-23°C) and humidity. The experiments were carried out in accordance with the institutional animal care and use committee guidelines and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Fingolimod was a generous gift from Hangzhou Tongming Scientific and Technologic Co., Ltd. (Hangzhou, China). Fingolimod was reconstituted in normal saline and prepared as eyedrops (pH = 7.3-7.5).
Study design. BALB/c mice were randomly divided into four groups (18 mice per group, six mice per time-point): fingolimod-treated groups at three different concentrations (0.01%, 0.1% and 0.5%) and an untreated control group. Each BALB/c mouse received fingolimod eyedrops (drop size = approximately 30 lL) three times daily at 8:00, 12:00 and 17:00. Mice were examined at 1 week, 1 month and 2 months after the commencement of treatment.
In vivo observations. To estimate food and water intake, water and feed for each study group were weighed daily. The daily changes in these weights were presumed as consumption by the mice. Additionally, at 1 week, 1 month and 2 months, the eyes were examined by slit-lamp microscope (SLM-6, Chongqing Kang HuaRui Ming technology co., LTD Beibei District, Chongqing City, China). The cornea was stained by fluoresce in sodium (Biodee Diagnostic, Beijing, China) and observed under the slit-lamp microscope. Images were recorded and analysed.
Tear IL-1b assay. To assess the minor and subtle changes at protein level in ocular surface, IL-1b in tear fluid was examined. Tear fluid washings were collected according to our previous study [16] . Briefly, 1.5 lL of 0.1% bovine serum albumin in phosphate-buffered saline was instilled into the conjunctival sac. A mixture of tear and buffer was collected with a 1-lL glass capillary tube via capillary action from the tear meniscus in the lateral canthus. Tear fluid washings of both eyes were collected three times on alternate days from eyes of six mice. The collected washings of six mice were combined as a single sample and stored at À80°C until assayed. Tear fluid washings were diluted by phosphate-buffered saline, and IL-1b levels in tear washing fluids were determined by ELISA kits for mouse IL-1b (Quantikine M Murine; R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. Absorbance at 450 nm was read by a Tecan Safire2 Multifunction Reader (Tecan Group, Ltd., Maennedorf, Switzerland) with the reference wavelength of 570 nm. The mean values of the three measurements were reported.
Leucocyte monitoring in peripheral blood. At 1 week, 1 month and 2 months after the commencement of treatment, six mice were deeply anaesthetized with 1% pentobarbital sodium (10 lL/g, intraperitoneal injection). About 0.5 mL peripheral blood samples was collected immediately from orbits with heparin tube. The cell counts and classification of blood cells including the leucocytes were examined and compared among different groups by a blood analyser (XT-4000i; Sysmex, Kobe, Japan).
Cornea and retina HE staining. After the mice were killed, the corneas and retinas were collected immediately and fixed with 4% paraformaldehyde in PBS for 24 hr, and then dehydrated sequentially with 10%, 20% and 30% sucrose solutions. The tissues were cryosectioned at 5 lm thickness, rehydrated in two changes of absolute alcohol for 5 min., 95% alcohol for 2 min., 70% alcohol for 2 min. and washed briefly in distilled water. Samples were stained in Harris haematoxylin solution for 8 min. and washed in running tap water for 5 min. Samples were destained in 1% acidic alcohol for 30 sec. and washed in running tap water for 1 min. They were then back blued in 0.2% ammonia water for 30 sec.-1 min. and washed in running tap water for 5 min., rinsed in 95% alcohol for 10 dips, then counterstained in eosin solution for 30 sec.-1 min. and dehydrated through 95% alcohol, two changes of absolute alcohol, 5 min. each time, cleared in two changes of xylene, 5 min. each time and mounted with xylene-based mounting medium. Finally, the samples were covered with neutral gum and observed under microscope.
Immunohistochemistry. The conjunctiva of mice in four groups and submandibular gland, liver, lung, kidney, adrenal gland and spleen in the 0.5% fingolimod group were collected and fixed with 4% PBSbuffered paraformaldehyde for 24 hr and then dehydrated sequentially with 10%, 20% and 30% sucrose solutions. After OCT embedding, specimens were cryo-sectioned at 5 lm thickness. The sections were air-dried at room temperature for at least 2 hr, then rinsed with PBS and treated with 3% hydrogen peroxide for 5 min. Sections were then blocked by 1% normal goat serum for 15 min. at room temperature. After the goat serum was removed, the sections were incubated with primary antibodies, that is rat leucocyte common antigen (LCA) monoclonal antibody (1:100; eBioscience, Santiago, CA, USA), in a humidified chamber at 4°C overnight. After being washed three times with PBS, the sections were treated with a peroxidase-labelled goat anti-rat IgG antibody (1:500; Chemicon, Millipore Chemicon, Billerica, Massachusetts, USA) for 1 hr at room temperature. A sample without primary antibody was used as a negative control. Visualization was performed with treatment of diaminobenzidine for 5 min.
Statistical analyses. Data are expressed as mean AE S.D. One-way ANOVA followed by F-test was used to compare values among study groups. A p-value of 0.05 or less was considered statistically significant.
Results
Adverse reactions in ocular surface tissue. Fingolimod was dissolved in normal saline with three different concentrations and instilled in ocular surface three times each day. We found that at 1-week time-point, in the 0.5% fingolimod group, BALB/c mice consumed less food and water. Other distinctive abnormal signs such as photophobia, catacleisis, oedema and point or patchy opacity in cornea were also observed under slit-lamp microscope. The cornea was positively stained by fluorescein sodium. After 1 month, the ocular changes became worse and corneal opacity persisted, with oedema of full-thickness cornea. Moreover, neovascularization was also found invading from the peripheral cornea. In contrast, we did not find any apparent sign or toxic reaction in 0.01% and 0.1% fingolimod groups including the intake of food and water compared with negative control group. In addition, there was no apparent sign of inflammation such as congestion or oedema in ocular surface tissue. The cornea was clear and transparent (figs 1-4).
Inflammatory reactions in the 0.5% fingolimod group. We observed adverse effects in ocular surface, especially oedema and nubecula, in cornea of the 0.5% fingolimod group. In view of this, we assayed IL-1b in tear fluid by ELISA and evaluated changes in morphology and structure of cornea and conjunctiva by HE staining and immunohistochemistry. We found that compared with baseline, the level of IL1b did not significantly change in the negative control, and 0.01% and 0.1% fingolimod groups. In contrast, it was sharply increased in the 0.5% fingolimod group. Moreover, we also found that the thickness of cornea in the 0.5% fingolimod group was increased, likely due to oedema. Fibres in the stromal layer were disarranged, and the endothelial layer was invariably detached from the stromal layer. There was LCApositive cells infiltrated between conjunctival epithelial and tarsus of conjunctiva early in the first week, which continued till the mice were killed. In contrast, we did not find such inflammatory reactions in the two lower-concentration groups Fig. 1 . Intake of food and water in the negative control group and three fingolimod groups. The intake of food and water of BALB/c mice in the control group and three fingolimod groups was observed. Data were recorded and compared among four groups. The results showed that the food and water intake of mice in 0.5% fingolimod were significantly less than the negative control group and other two lower-concentration groups. The data were the mean AE S.D. (n = 6). *p < 0.05, negative control, 0.01% fingolimod group, 0.1% fingolimod group versus 0.5% fingolimod group. and the negative control group (figs 5-7). These results were consistent with our in vivo observations.
Fingolimod concentration and leucocytes in peripheral blood. Previous studies reported that fingolimod exerts immunoregulating roles of lymphopenia in peripheral blood. The potential mechanism is suppression of the recirculation of lymphocyte and sequestration of these cells into lymph nodes and Peyer's patches [12, 18] . Although our study focused on the efficacy of fingolimod as eyedrops in ocular surface disease, we chose to monitor the fingolimod concentration and potential change of lymphocyte in peripheral blood in order to appraise its safety. Hence, we measured and analysed fingolimod concentration and blood cells in peripheral blood of BALB/c mice in our study. During the observing period, we did not detect fingolimod in peripheral blood (data not shown). We also did not find a significant change in blood cells in peripheral blood, including the amount of leucocyte and the proportion of lymphocyte in three fingolimod-treated groups (table 1, p > 0.05).
Change in retina and selected organs.
In view of adverse effects reported in previous studies [13] [14] [15] , we explored the morphology and structure of retina and selected systemic organs, especially organs involved in the metabolism and excretion of fingolimod. We analysed 3-month samples in the 0.5% fingolimod group and assessed the structure and inflammatory responses in the retina. We did not find significant morphologic change or inflammation in retina. Also, we explored selected organs including submandibular gland, liver, lung, kidney, adrenal gland and spleen by immunohistochemistry, and we did not find any abnormal sign in those organs (figs 8 and 9).
Discussion
Fingolimod has been reported to be highly effective in attenuating multiple sclerosis, prolonging allograft survival, relieving ischaemia-reperfusion injury, protecting nerve cells, inhibiting proliferation and metastasis of sarcoma cells, preventing diabetes as well as treating autoimmune diseases [19] [20] [21] [22] [23] .
Recently, fingolimod was also reported efficacious in treating autoimmune uveitis and prolonging corneal graft survival [18, 24, 25] . However, adverse effects were also reported. In recent phase III trials, the incidence of adverse effects related to fingolimod was described, including infections, increased levels of alanine aminotransferase, bradycardia, atrioventricular block, hypertension and macular oedema [26, 27] . On the other (L) By the end of 3 months, the oedema and active reaction in cornea were not apparent. Instead, neovascularization was found progressively proliferated (yellow arrows), and the cornea was decompensated in some mice. Six BALB/c mice were examined in each group at each time-point, and all the BALB/c mice in the 0.5% fingolimod group showed varying adverse effects in corneas.
hand, in our previous study, we also found that 0.5% fingolimod showed certain undesirable results while 0.05% or lower concentration did not have significant adverse effect in ocular surface [16] . In view of this, we consider it necessary to evaluate the safety profile of fingolimod as topical formulations in ocular surface tissue. Adverse reactions were found in the ocular surface of BALB/c mice in the 0.5% fingolimod group, but not in the 0.1% and 0.01% fingolimod groups. In the early time-point, hyperaemia and oedema were observed in ocular surface and corneal oedema was also found under slit-lamp microscope. The adverse effects were exacerbated with time, and neovascularization was also found in peripheral cornea of some mice. Eventually conjunctival scars invaded into cornea accompanied by neovascularization, which denoted a sign of corneal decompensation. In contrast, we did not detect such effects in the 0.1% and 0.01% fingolimod-treated groups (figs 2-4). This may suggest that fingolimod, although is an immunoregulating prodrug, also produces chemical toxicity locally in ocular surface at high concentration.
We also measured IL-1b level in tear fluid to appraise an early stage of pathogenesis. Our results showed that the level of IL-1b in tear fluid was found to be sharply increased in the 0.5% fingolimod group 1 month after start of treatment, which stayed at a high level till the mice were killed. We did not find a significant change in tear fluid during 3 months in the negative control group and the other lower-concentration fingolimod groups ( fig. 5) . Moreover, corneal HE staining showed a disarranged morphology and structure of cornea in the 0.5% fingolimod group, accompanied by corneal oedema. Immunohistochemical results also exhibited an inflammatory reaction in conjunctiva, leucocytes infiltrated between subconjunctiva and tarsus in the 0.5% fingolimod group. However, we did not find any pathological change in the negative control and the other two lower fingolimod-treated groups. These results corroborate with in vivo observation and tear fluid detection (figs 6 and 7).
It should be noted that, theoretically, leucocytes cannot be possibly found in the ocular surface tissue of BALB/c mice in the fingolimod-treated groups, for fingolimod itself is a leucocyte immunoregulator. In this way, it seemed that we harvested a contradictory result. We believe it worth specially addressed and analysed. It is true that the role of fingolimod is to inhibit leucocytes, while when the drug concentration is much higher than the tissue can withstand, then the chemical toxic reactions prevailed. In this case, the ocular manifestations are mainly toxic reactions instead of fingolimod therapy. It is well documented that inflammatory reaction is one of the typical characteristics of toxic effects. Thus, it seemed interpretable and reasonable to appraise this A B C D Fig. 4 . Fluorescence stained in cornea and observed under cobalt-blue light slit-lamp microscope; the negative control group and 0.5% fingolimod group at different stages were compared. Under cobalt-blue light, if there is lesion in cornea, it will be stained by fluorescein, and the positivestained place will be green. Otherwise, it will be blue. (A) The cornea was normal in the negative control group at 2 months, and the fluorescence staining was negative. (B) In comparison, in the 0.5% fingolimod group, oedema and point or patchy opacity in cornea was found by fluorescence staining in the first week. (C) After 1 month, oedema and opacity persisted, along with neovascularization proliferated and invaded from corneal limbus to the central cornea. (D) By the end of 2 months, the cornea was deteriorated, with only point fluorescence staining which denoted less active inflammation but decompensation in cornea. Six BALB/c mice were examined in the negative control group and 0.5% fingolimod group at each time-point, and all the BALB/c mice in the 0.5% fingolimod group showed varying oedema, opacity and neovascularization in corneas.
result. Hence, our results clearly indicated that, as eyedrops, there were definitely adverse reaction effects in 0.5% fingolimod or higher concentration. Actually, our previous study has indicated that the optimal concentration range of fingolimod as eyedrops is between 0.005% and 0.05% [16] . Thus, we may outline a safe and therapeutic concentration range of fingolimod lies between 0.005% and 0.1%. These valuable data may provide a recommendation for future development and application of this compound in DED treatment of patients. It is known that fingolimod plays an immunoregulating role by inhibiting lymphocyte and sequester them into lymph nodes and Peyer's patches [12, 17] . In views of this, we have a continuous monitoring of blood cells in peripheral blood, we collected blood samples in orbital cavity after the mice were killed, analysed and compared the blood cells data among the negative control group and three fingolimod-treated groups. Our data showed that there was no significant abnormality in the amount of leucocytes and proportions of lymphocyte (table 1) . Moreover, we also conducted a detection of fingolimod in peripheral blood. We set the minimum concentration 9.0 9 10 À4 mg/mL. During a period of 3 months, we did not detect fingolimod in peripheral blood (data not shown).
We believe that this is mainly because of a relatively low concentration of fingolimod solution as well as a limited absorption into the systemic circulation via local administration in ocular surface. As our total observation period was 3 months, we believe these data may provide a reliable reference for a safe appraisal of peripheral blood during fingolimod treatment in the ocular surface. Fingolimod eyedrops did not produce histological, morphological or inflammatory changes in retina and systemic organs. It is reported that fingolimod may result in changes in the macula and vital organs by systemic administration [28, 29] . In the current study, we collected retinas from four groups and detected by HE staining. As there is no macula in rodents, we observed the retinas and compared the thickness of the central Fig. 5 . IL-1b level in tear fluid washings were detected and compared among negative control and three fingolimod groups (18 mice in each group). Tear fluid washings were collected in each group at 1 month, 2 months and 3 months, respectively, after intervention. After 1.5 lL of phosphate-buffered saline containing 0.1% bovine serum albumin was instilled into the conjunctival sac, 1.0 lL of mixture of tear fluid and phosphate-buffered saline was collected with a 1-lL glass capillary tube via capillary action from the tear meniscus in the lateral canthus. Tear fluid washings were collected three times on alternate days from both eyes of six mice, the total tear fluid washings of six mice were collected as a single sample, three samples in the same group were analysed, respectively, and the averaged values were reported. The data were the mean AE S.D. (n = 6).*p < 0.01, negative control, 0.01% fingolimod group, 0.1% fingolimod group versus 0.5% fingolimod group.
. HE staining of cornea in the negative control and three fingolimod-treated groups (A-C, E-G, I-K). In the negative control group, 0.01% and 0.1% fingolimod groups, the thickness and morphology of cornea remained normal during 2 months. (D, H, L) In contrast, in the 0.5% fingolimod group, the thickness of cornea increased, and oedema of corneal stromal was apparent. The corneal structures and layers were deranged and most of the endothelium detached from the stroma (yellow arrows). The thickness of cornea in the four groups was recorded and compared under microscope with the same magnification. The negative control, 0.01% fingolimod and 0.1% fingolimod versus 0.5% fingolimod: p < 0.01, six corneas from six BALB/c mice were examined in each group, and the results showed that the thickness and structure of all corneas in 0.5% fingolimod were significantly abnormal compared with the negative control group, 0.01% fingolimod group and 0.1% fingolimod group.
part of retinas between four groups and did not find any significant sign of damage ( fig. 8 ). We also examined selected organs by immunohistochemistry and did not find any significant lesion and infiltrating leucocytes ( fig. 9 ). This result is also consistent with the data of peripheral blood cells and fingolimod concentration detection, which implied that
Immunohistochemical results of conjunctiva. LCA was employed as an inflammatory marker to detect and appraise toxic reactions and secondary inflammation in conjunctiva (A-C, E-G, I-K). During 2 months, the conjunctiva of BALB/c mice did not show any significant lesion or inflammation in the negative control group, and 0.01% and 0.1% fingolimod groups, and the conjunctival structure was in order. (D, H, L). In the 0.5% fingolimod group, there were abundant leucocytes infiltrated between palpebral conjunctiva and tarsus (yellow arrows) at 1 week, and the conjunctival inflammation persisted till the BALB/c mice were killed after 2 months. Six conjunctival tissues from six BALB/c mice were detected with LCA marker in each group, and the results showed that there were always LCA-positive cells infiltrated in conjunctiva of BALB/c mice in the 0.5% fingolimod group. Detection and comparison of blood cells in peripheral blood. Blood cells in peripheral blood were collected and analysed at 1 week, 1 month and 2 months after commencement of fingolimod treatment. The results showed that there was no significant difference in levels of blood cells including the subtypes of leucocytes among the negative control group and three fingolimod groups during 2-month observation. Data are mean AE S.D.
(n = 6). There is no significant difference among the study groups (p > 0.05). LYM, lymphocyte; MONO, monocyte; RBC, red blood cell; PLT, platelet.
local administration of fingolimod in ocular surface does not produce significant damage to the condition of retina, systemic organs and blood cells during long-term treatment. This is quite important and meaningful because many ocular surface diseases, including DED, usually need a long-lasting therapy to assure a therapeutic effect. Fig. 8 . HE staining of retina in each group at 3-month time-point. In order to observe and appraise the toxic and inflammatory reactions to retina, the BALB/c mice from four groups were deeply anaesthetized and killed at 3 months, the eyeballs were collected and HE staining was performed. The results showed that fingolimod applied as eyedrops in ocular surface tissue did not result in any significant changes in retina. The thickness of central retina in block diagram in the four groups was recorded and compared under microscope with the same magnification; the data were average AE S.D. We examined six eyeballs in each group, and the results showed that the structure and thickness of retina in three fingolimod groups were normal. There was no significant change among the four groups. #: The thickness of central retina in block diagram in the four groups was recorded and compared under microscope with the same magnification, the data were average AE S.D, p>0.05. Fig. 9 . Immunohistochemical results of systemic organs from the 0.5% fingolimod group at 2 months. In order to observe and appraise the toxic and inflammatory reactions to morphology and structure of systemic organs, submaxillary gland, adrenal gland, lung, liver, kidney and spleen of BALB/c mice were collected from the highest concentration (0.5% fingolimod) group and analysed by LCA marker. (A-F) The immunohistochemical results showed that fingolimod applied as eyedrops in ocular surface tissue did not result in any significant changes in the morphology and structure of systemic organs. Also there were no positive-stained cells in these organs during 2-month observation. We examined six BALB/c mice in the 0.5% fingolimod group, but we did not find any significant lesion or inflammation in those organs of the BALB/c mice.
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In summary, fingolimod was proven to be highly effective in alleviating DED in rodent model. At 0.1% or lower concentration, this drug seems to be safe. We recommend a range of 0.005%-0.1% of fingolimod eyedrops for treatment of DED.
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